KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Account Payables: 2018-2025

Historic Change in Account Payables for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $1.4 million.

  • Castle Biosciences' Change in Account Payables rose 165.33% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 420.43%. This contributed to the annual value of -$4.4 million for FY2024, which is 176.61% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Change in Account Payables is $1.4 million, which was up 30.91% from $1.1 million recorded in Q2 2025.
  • Castle Biosciences' Change in Account Payables' 5-year high stood at $3.9 million during Q1 2023, with a 5-year trough of -$2.2 million in Q3 2024.
  • For the 3-year period, Castle Biosciences' Change in Account Payables averaged around $402,727, with its median value being -$378,000 (2023).
  • Per our database at Business Quant, Castle Biosciences' Change in Account Payables crashed by 1,935.71% in 2021 and then skyrocketed by 1,983.42% in 2023.
  • Castle Biosciences' Change in Account Payables (Quarterly) stood at -$855,000 in 2021, then plummeted by 83.98% to -$1.6 million in 2022, then spiked by 291.61% to $3.0 million in 2023, then crashed by 118.91% to -$570,000 in 2024, then spiked by 165.33% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.1 million for Q2 2025, and $615,000 during Q1 2025.